Business Context and Reporting Period
Company: Dyadic International, Inc. (formerly CCP Worldwide, Inc.)
Filing Date: October 29, 2004
Reporting Period: Current Report (Form 8-K) regarding transactions consummated on October 29, 2004.
On October 29, 2004, the Company consummated three related transactions: (1) a reverse merger with Dyadic International, Inc., a Florida corporation ("Dyadic-Florida"), resulting in Dyadic-Florida becoming a wholly-owned subsidiary and the Company changing its name to Dyadic International, Inc.; (2) a split-off of its former operating subsidiary, Custom Craft Packaging Company, Inc., to former CEO David Allison; and (3) the initial closing of a private placement offering of Investment Units.
Following these transactions, the Company's sole business operations are those of Dyadic-Florida, a biotechnology company focused on the development and sale of industrial enzymes and the development of a proprietary "C1 Expression System" for therapeutic proteins.
Key Financial Metrics
Capital Raised: The Company derived gross proceeds of $25,242,000 and net proceeds of approximately $23,100,000 from the sale of 7,580,313 Investment Units at $3.33 per unit.
Debt Obligations: As of the consummation of the Merger, the Company is indebted to principal stockholders (Mark A. Emalfarb and The Francisco Trust) in the aggregate amount of $4,002,813. This includes convertible notes and a revolving note, all due January 1, 2007. Additionally, the Company owes approximately $1,143,000 to its Polish contract manufacturer for plant modification costs.
Historical Performance: The filing notes that since 1998, the Company has incurred net losses of approximately $16 million through December 31, 2003, including a net loss of approximately $7.3 million for the year ended December 31, 2003. As of June 30, 2004, the accumulated deficit was approximately $17.3 million.
Revenue: The filing does not provide specific revenue figures for the current period. It notes that prior to the merger, the Industrial Enzymes Business generated revenues of $16.6 million in 2003, while the BioSciences Business generated nominal revenues ($150,000 in 2003).
Liquidity: The Company expects to continue to incur net losses and negative cash flow as it accelerates R&D and expands sales and marketing. It anticipates needing significant additional capital in the future.
Material Changes Versus Prior Period
- Change in Control: The Company underwent a reverse merger. Former shareholders of Dyadic-Florida now own approximately 56.7% to 58% of the outstanding Common Stock. Mark A. Emalfarb and Stephen J. Warner were appointed to the Board of Directors, replacing the previous management team.
- Business Pivot: The Company disposed of its only prior operating business (Custom Craft Packaging) and is now exclusively engaged in the biotechnology business of Dyadic-Florida (Industrial Enzymes and BioSciences).
- Capital Structure: The Company issued 12,580,895 shares in the merger and 7,580,313 shares in the private offering. Total outstanding shares as of October 29, 2004, were 22,182,214.
- Debt Restructuring: Existing debt to principal stockholders was amended to extend the due date to January 1, 2007, and conversion/exercise prices were fixed at $3.33 per share.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The Company plans to grow its Industrial Enzymes Business by diversifying into pulp and paper, animal feed, and food markets. For the BioSciences Business, the strategy is to collaborate with pharmaceutical companies to express therapeutic proteins using the C1 Expression System. The Company does not anticipate material revenues from the BioSciences Business sooner than 2006.
Unusual Items:
- Stock for Services/Assets: The Company agreed to issue 300,300 shares valued at $3.33 per share to a contract manufacturer (BTR) for R&D services and 300,300 shares to a real estate developer for land purchase.
- Debt for Equity: CEO Mark A. Emalfarb exchanged $1,225,000 of indebtedness for Co-Investment Units.
Material Risks:
- Profitability: The Company has a history of net losses and expects to continue incurring losses. It may not achieve profitability.
- Manufacturing Dependency: The Company relies entirely on contract manufacturers, primarily Polfa Tarchomin, SA in Poland. If this manufacturer fails to expand capacity or perform, sales could be impaired.
- Regulatory Approval: The BioSciences Business is subject to lengthy and uncertain FDA and foreign regulatory approval processes for therapeutic proteins.
- Liquidity of Stock: There is no established trading market for the Common Stock, and the shares are subject to "penny stock" rules, which may reduce liquidity.
- Concentration of Ownership: Officers, directors, and principal stockholders control approximately 46.7% of the outstanding Common Stock.
Important Facts for Investor Verification
- Registration Statement Deadline: The Company is obligated to file a registration statement for the resale of shares by April 2, 2005. Failure to do so triggers liquidated damages of 1% of gross proceeds per month of delay.
- Debt Security: All of the Company's assets are mortgaged or pledged to secure the approximately $4.0 million indebtedness owed to principal stockholders Emalfarb and the Francisco Trust.
- Manufacturing Capacity: Verify the status of the Polish contract manufacturer's (Polfa) ability to fund and complete necessary modernization and expansion of facilities, which is critical for future growth.
- Lock-Up Agreements: Approximately 35.8% of outstanding shares are subject to lock-up agreements restricting sales for six months to one year following the registration date.
- Financial Statements: The filing explicitly states that financial statements of the acquired business and pro forma financial information are not yet available and will be filed by amendment within 71 days.